TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03092791

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)
Description: sIPV intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference IPV
Description: Reference IPV intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reference IPV
Description: Reference IPV intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: sIPV Placebo
Description: sIPV placebo-matching intramuscular injection
Study: NCT03132974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sogyeonghwalhyeol-tang granule
Description: Sogyeonghwalhyeol-tang herbal extract granule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sogyeonghwalhyeol-tang granule with manipulation procedure
Description: Sogyeonghwalhyeol-tang herbal extract granule with manipulation procedure
Study: NCT04361383

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae plane block
Description: patients will receive ultrasound-guided quadratus lumborum block type 3 with 30 ml of bupivacaine 0.25% followed by general anesthesia.
Study: NCT03484494

Intervention type: DEVICE
Group type: OTHER
Intervention: Low Field Magnetic Stimulation
Description: Low Field Magnetic Stimulation is an application of a series of electromagnetic pulses to the brain through a small cylinder that the subject places the top of their head inside.

Intervention type: DEVICE
Group type: OTHER
Intervention: Low Field Magnetic Stimulation
Description: Low Field Magnetic Stimulation is an application of a series of electromagnetic pulses to the brain through a small cylinder that the subject places the top of their head inside.
Study: NCT02382562

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Activation Intervention
Description: Clinical psychologists (investigators) will instruct the participant in ways to become more active in life, particularly with regards to activities that the participant finds pleasurable and meaningful. The intervention will take one hour to complete. Following the intervention, the participant will receive brief, weekly text or email reminders for the next 4 weeks (total of 4) to engage in pleasurable and meaningful activities during the week.
Study: NCT06119347

Intervention type: DRUG
Intervention: AntiVEGF
Description: anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab;

Intervention type: DRUG
Intervention: ICIs
Description: immune checkpoint inhibitors include Pembrolizumab, Sintilimab, toripalimab, Camrelizumab, Tislelizumab.
Study: NCT03587337

Intervention type: OTHER
Intervention: POEM
Description: Pt. are going to submit a POEM procedure.

Intervention type: OTHER
Intervention: POEM
Description: Pt. are going to submit a POEM procedure.
Study: NCT01473745

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: conventional alar base cinch
Description: The conventional suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified alar base cinch
Description: The modified suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
Study: NCT00404885

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PO BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.2 mg/kg, twice a day (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.4 mg/kg, twice a day (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LX211
Description: 0.6 mg/kg, twice a day (BID)
Study: NCT02414009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die refracted in two daily doses from day 1 to day 14 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Patients in Arm A will receive temozolomide 150 mg/mq/die refracted in two daily doses starting on day 10 to 14 every 28 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Patients in Arm B will receive FOLFIRI chemotherapy starting Day 1 q2w (every cycle) starting on Day 1 of Cycle 1. FOLFIRI consists of irinotecan (starting dose of 180 mg/m2) on day one only; 5-FU (starting bolus and 22-hour infusional doses of 400 mg/m2 and 600 mg/m2, respectively), and leucovorin (racemic, starting dose of 200 mg/m2 or L-form, starting dose of 100 mg/m2) for two consecutive days.
Study: NCT01295203

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: website assess
Description: The internet intervention group were given assess to the intervention website which included a personal page with tailored physical activity advice and a personal profile together with Recommendations and general training programs.
Study: NCT00673608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Description: Deferasirox up to 40mg/kg/day, PO, Dispersible tablets, taken once daily
Study: NCT01190644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: single 35 mg SC dose of sotatercept on study Day 1, Day 43, and Day 85
Study: NCT02471456

Intervention type: OTHER
Intervention: Quality of Life Questionnaire
Description: Quality of Life Questionnaire will be completed at least 1 year after their surgery.

Intervention type: OTHER
Intervention: Quality of Life Questionnaire
Description: Quality of Life Questionnaire will be completed at least 1 year after their surgery.

Intervention type: OTHER
Intervention: MACCE review
Description: MACCE will be assessed by contacting the patient's GP and/or Cardiologist at least 1 year after their surgery.

Intervention type: OTHER
Intervention: MACCE review
Description: MACCE will be assessed by contacting the patient's GP and/or Cardiologist at least 1 year after their surgery.
Study: NCT00807703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Select Stim
Description: Select Stim: see summary
Study: NCT02450695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Study: NCT03480113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: mindful breath, body scan, sitting meditation and walking meditation and so on.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical fitness intervention
Description: giving the lessons of stretch exercise, aerobics to strength muscle and lung fuctions.
Study: NCT03969576

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DEB-TACE
Description: Patients in the DEB-TACE group received a maximum dose of 4 ml of DC bead (diameter 75-500 um) loaded with a maximum dose of 150 mg of anthracyclines drugs, such as doxorubicin. The anticancer agents and the diameter of DC Bead for individual patient will be selected according to the common clinical practice of each center. Treatment endpoint consisted of stasis of flow within feeding vessel(s) or completed delivery of maximum single-session dose of 150 mg doxorubicin. TACE will be repeated on demand according to the radiological response.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cTACE
Description: Patients in the cTACE group were treated with anthracyclines, such as doxorubicin, in a mixture of lipiodol. Administration of the anticancer in oil emulsion was followed by injection of embolic materials such as gelfoam or PVA particles until complete stasis in segmental or subsegmental arterial branches. the tumor-feeding vessels should be superselected whenever possible. The anticancer agents for individual patient will be selected according to the common clinical practice of each center. TACE will be repeated on demand according to the radiological response.
Study: NCT01042249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle training
Description: 12 week training program including home exercises
Study: NCT01026298

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FDA-Approved Treatment
Description: 8 weeks of treatment with Continuous Positive Airway Pressure (CPAP)
Study: NCT00575042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)
Description: 160 mg per day for 1 year
Study: NCT03038269

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Upper Extremity Robotics, tDCS
Description: Participant will receive 20 minutes of non-invasive brain stimulation followed by one hour of shoulder/wrist robotic training.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Upper Extremity Robotics, tDCS
Description: Participant will receive 20 minutes of non-invasive brain stimulation followed by one hour of shoulder/wrist robotic training.
Study: NCT00726271

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: light olive oil, fish oil capsules, flax seed oil capsules
Description: fish oil 1000 mg capsules three daily flax seed oil 1000 mg capsules three daily light olive oil 30 ml to 60 ml daily(weight less than 160 pounds, 30 ml/ weight 160-200 pounds 45 ml/ weight over 200 pounds 60 ml)
Study: NCT00640744

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: Atorvastatin 80 mg tablet/day for 3 months
Study: NCT01929876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 10 milligram (mg) (2\* 5 mg capsules) will be administered orally on Day 1 of Period 1 and Day 4 of Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg oral solution will be administered once daily from Day 1 to Day 14 of Period 2
Study: NCT04707950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 100 milligram/Milliliter
Description: Participants will be divided into two groups: a study group \& a control group. In addition to the standard management, the study group will be given TXA 1 gm (100 mg/ml) slowly intravenous infusion during delivery after clamping of the cord (administered over 10 minutes at 1 ml/minute).~The second dose of TXA 1 g Intravenous can be given if:~* Bleeding continues after 30 minutes~* Bleeding restarts within 24 hours of completing the first dose While the control group will not be given TXA and we will compare the results in both groups (amount of blood loss during operation to assess the efficacy of TXA in the prevention of PPH and reduction of intraoperative and postoperative blood loss and to assess its safety and benefit in the reduction of incidence of hysterectomy or blood transfusion requirements).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: both groups will be given oxytocin as a standard management

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: both groups will be given oxytocin as a standard management
Study: NCT00755729

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative Oral Carbohydrate
Description: Patients in OCH group consumed 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour

Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: Preoperative Oral Carbohydrate
Description: Patients in FSD group were fasted from midnight the night before surgery, and no preoperative oral carbohydrate loading
Study: NCT03132974

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with manipulation procedure
Description: Placebo granule with manipulation procedure
Study: NCT03838029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol and etodolac
Description: A perioperative combined drug regimen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02169557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Study: NCT00656201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crinone 8% Vaginal Gel
Description: Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Progesterone
Description: Progesterone-50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.
Study: NCT03617068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocos Nucifera Whole
Description: Applying the Cocos Nucifera Whole cream for 2 weeks, on both of arms. We evaluated the score of hand dermatitis using Hand Eczema Score Index ( HECSI), transepidermal water loss (TEWL), and Skin capacitance

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocos Nucifera Whole
Description: Applying the Cocos Nucifera Whole cream for 2 weeks, on both of arms. We evaluated the score of hand dermatitis using Hand Eczema Score Index ( HECSI), transepidermal water loss (TEWL), and Skin capacitance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cocos Nucifera Whole
Description: For dermatopharmacokinetic evaluation using tape/ skin stripping

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocos Nucifera Whole
Description: For dermatopharmacokinetic evaluation using tape/ skin stripping
Study: NCT00958711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unite Biomatrix
Description: Collagen based, decellularized equine pericardial dressing for skin surface wounds

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline and Gauze
Description: gauze moistened with sterile saline
Study: NCT03834623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Description: Oral CC-122 at 2 mg daily, 5 days out of 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240 mg Nivolumab intravenously days 1 and 15 in each 28 day cycle
Study: NCT04028817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photobiomodulation
Description: the intervention will occur twice a week, 18 sessions will be performed, during the sessions will be applied sublingual laser in a single point, with wavelength of 808 nm, diameter of 0.4 cm, with irradiance of 0.8 w / cm2, for 360 s, the laser applied will be of continuous wave with energy of 36J.
Study: NCT00048165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Daclizumab will be administered as 1 mg/kg IV within 12 hours post-op (Day 1), and Days 8, 22, 36 and 50.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone will be administered as 500-1000 mg IV and peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering till 0.0-0.15 mg/kg/day (up to 365 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone will be administered as 500-1000 mg IV and peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering till 0.0-0.15 mg/kg/day (up to 365 days).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil will be administered as 1.5 grams bid begun post-op, either IV or orally as required up to 365 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil will be administered as 1.5 grams bid begun post-op, either IV or orally as required up to 365 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered on Days 1, 8, 22, 36, and 50.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Cyclosporine will be administered as 1-4 mg/kg IV or 2-6 mg/kg orally up to 365 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclosporine
Description: Cyclosporine will be administered as 1-4 mg/kg IV or 2-6 mg/kg orally up to 365 days.
Study: NCT02792335

Intervention type: DRUG
Intervention: apixaban

Intervention type: DRUG
Intervention: apixaban

Intervention type: DRUG
Intervention: dabigatran

Intervention type: DRUG
Intervention: dabigatran

Intervention type: DRUG
Intervention: rivaroxaban

Intervention type: DRUG
Intervention: rivaroxaban

Intervention type: DRUG
Intervention: warfarin
Study: NCT01756248

Intervention type: DRUG
Intervention: Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)
Description: Patients treated with EYLEA under practical manner for AMD.
Study: NCT02394015

Intervention type: DRUG
Intervention: Trabectedin and Pegylated Liposomal Doxorubicin
Description: Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014
Study: NCT02786706

Intervention type: DEVICE
Intervention: Optic nerve ultrasound
Description: All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
Study: NCT04125940

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resync
Description: The product known as Resync contains a blend of nitrate-rich foods including beetroot, red spinach, turmeric, ginger root, and aronia berry extracts. Resync is sold commercially and marketed as an ergogenic aid and/or exercise recovery aid.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resync
Description: The product known as Resync contains a blend of nitrate-rich foods including beetroot, red spinach, turmeric, ginger root, and aronia berry extracts. Resync is sold commercially and marketed as an ergogenic aid and/or exercise recovery aid.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resync + Collagen
Description: 17g Collagen + 2g Resync + 1g Carbohydrate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12oz water + food coloring
Study: NCT04292145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Application
Description: The use of an application for relaxation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Only
Description: The individual's personal method to relax.
Study: NCT04171856

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REAplan(R)
Description: motor skill learning with the REAplan(R) rehabilitation robot, to be perfomed with the affected arm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REAplan(R)
Description: motor skill learning with the REAplan(R) rehabilitation robot, to be perfomed with the affected arm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: REAplan(R)
Description: motor skill learning with the REAplan(R) rehabilitation robot, to be perfomed with the affected arm
Study: NCT00466206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Mini-Mover Procedure (3MP)
Description: A rare earth magnet encased in FDA-approved titanium will be implanted securely on the outer surface of the lower end of the sternum in patients with pectus excavatum. This is accomplished as an outpatient procedure, under brief general anesthesia.~A 2-inch transverse skinline incision is made at the junction of the sternum and xyphoid and the space in front and behind the sternum is dissected bluntly. The titanium can containing the magnet is securely fixed to the sternum by screwing it into a titanium fixation disk in front of the sternum. The procedure takes 1/2-hour, and the patient can go home the same day.~In another outpatient procedure, the Magnimplant is explanted 18 months after implantation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnatract (external magnet in a removable external brace)
Description: An external orthotic device Magnatract which includes an external magnet in a removable brace is fitted specifically to the patient's chest wall deformity. A calibrated meter in the external device measures the force applied between the two magnets. When the patient and family are comfortable with the device and comfort and skin condition have been assessed, the patient will be allowed to take the Magnatract home and begin the process of gradually advancing the sternum forward as the abnormal costal cartilage is reformed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3MP (Magnetic Mini-Mover Procedure)
Description: * Subject has EKG performed to measure baseline cardiac activity.~* Magnimplant is implanted.~* After one week, Magnatract is fitted.~* Chest x-ray and 2nd EKG performed 30 days post-implantation.~* Patient and parents complete QoL questionnaire 30d post-implantation.~* Patient seen weekly for first month post-implantation to assess comfort and skin condition. Thereafter, will be seen monthly.~* At each monthly visit, patient will have lateral and anterior-posterior chest X-rays to monitor sternal correction.~* At each visit data logger is downloaded to measure strength of pull since last visit and amount of wear-time.~* Magnimplant explanted 18 months later as 1/2-hr outpatient procedure.~* CT scan and third EKG performed after explanation.~* Patient and parents complete QOL questionnaires after explantation and 1 yr post-explantation.